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Human papillomavirus (HPV) infection is thought to be a necessary but not sufficient cause of most cases of cervical cancer. Since oral
contraceptive use for long durations is associated with an increased risk of cervical cancer, it is important to know whether HPV
infection is more common in oral contraceptive users. We present a systematic review of 19 epidemiological studies of the risk of
genital HPV infection and oral contraceptive use. There was no evidence for a strong positive or negative association between HPV
positivity and ever use or long duration use of oral contraceptives. The limited data available, the presence of heterogeneity between
studies and the possibility of bias and confounding mean, however, that these results must be interpreted cautiously. Further studies
are needed to confirm these findings and to investigate possible relations between oral contraceptive use and the persistence and
detectability of cervical HPV infection.
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Infection with certain ‘high-risk’ types of the human papilloma-
virus (HPV) is thought to be a necessary but not sufficient cause of
most cases of cervical cancer (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 1999; Walboomers
et al, 1999). In recent analyses of data from case–control and
cohort studies, an increased risk of cervical cancer with increasing
duration of oral contraceptive use was confirmed both in all
women and in HPV positive women (Moreno et al, 2002; Smith
et al, 2003). This suggests that long duration use of oral
contraceptive may influence the development of cervical cancer
in women infected with HPV, however in interpreting these results
it is important to know whether such use of oral contraceptives is
itself associated with HPV infection. We have reviewed available
evidence from epidemiological studies on any relation between the
use of oral contraceptives and genital HPV infection.
METHODS
Studies were identified through a search of MEDLINE (1966–
August 2002) using the search terms ‘papillomavirus’, search
restricted to human studies (pre-1994) or ‘papillomavirus, human’
(1994–2002) and ‘risk factors’, and supplemented by references
from identified studies. Two studies then in press (Anh et al, 2003;
Shin et al, 2003) were obtained from groups reporting relevant
data at the International Papillomavirus Conferences, 2000–2002.
Studies were eligible for inclusion in this review if they had: (i) at
least 200 subjects with normal cervical cytology or from a
population with ‘mixed’ normal and abnormal cytology but at
relatively low risk for cytological abnormality, such as general
population surveys or routine screening or gynaecological clinics
(studies of women attending colposcopy clinics or with conditions
such as HIV infection, likely to be associated with a substantially
increased risk of cervical abnormality, were excluded); (ii) any
measure of genital HPV infection as the outcome; (iii) information
on oral contraceptive use; and (iv) relative risk estimated for HPV
positivity in oral contraceptive users vs never users either adjusted
for age, or calculated for age-matched or age-restricted subjects.
The most adjusted relative risk available was used for analysis. No
restriction was placed on the language of publication. The term
‘HPV positivity’ is used to reflect the fact that what is measured by
the various tests for HPV is detectable HPV rather than,
necessarily, underlying HPV infection. ‘High-risk’ (oncogenic)
and ‘low-risk’ (nononcogenic) HPV types were as defined in each
eligible study; all studies included types 16 and 18 in high-risk and
types 6 and 11 in low-risk groups, but studies varied with regard to
the number and classification of other types.
In most studies, the term ‘oral contraceptive’ was used
irrespective of the dose or formulation of contraceptive pills and
it was not possible to distinguish in these studies between the use
of combined or progestogen-only pills. It is likely, however, that
the large majority of oral contraceptive users had used prepara-
tions containing combined oestrogen and progestogen (Collabora-
tive Group on Hormonal Factors in Breast Cancer, 1996; IARC
Working Group on the Evaluation of Carcinogenic Risks to
Humans, 1999).
For analysing the effect of duration of oral contraceptive use,
results were grouped as ‘short duration’ (less than 5 years use),
‘medium duration’ (5–9 years use), and ‘long duration’ (10 or
more years use), with published results allocated to the most
appropriate group. For studies that had more than one data point
within a duration category, data were combined using the method
of generalised least squares taking into account the correlations
between the relative risks being combined (Berrington and Cox, in
press). In this analysis, current use of oral contraceptives is use
described as ‘current’ or use within the past 12 months and past
use is use described as ‘past’ or use that ceased more than 12
months in the past.
The results are summarised graphically in the figures, which
show relative risks for HPV positivity in users of oral contra-
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yTable 1 Epidemiological studies eligible for this review of the relation between human papillomavirus (HPV) positivity and use of oral contraceptives
Study Country Year Design
Number of
subjects
with HPV
and OC
data Cytology HPV measure HPV type
% HPV positive
in study
RR adjusted fora
Sexual
partners Other
Kjaer et al
(1990)
Denmark,
Greenland
1986 C/s population 1114 Mixed FISH Any 14 Yes Area, cytology, age at first OC
use
High risk: 16,18 12 Yes Area, cytology
Low risk: 6,11 7 Yes Area, parity
Ley et al (1991) USA 1989 C/s college 467 Mixed PCR MY09/11 Any 46 Yes Race
Karlsson et al
(1995)
Sweden 1989 C/s population 526 Mixed PCR MY09/11, GP5/6 Any 22 No —
Burk et al (1996) USA 1992–94 C/s college 602 Mixed PCR MY09/11,
Southern blot
Any 28 No —
Kjaer et al
(1997)
Denmark 1991–93 C/s population 956 Normal PCR GP5/6 Any 15 Yes Parity, condom use
High risk: 16, 18+ 11 Yes Chlamydia
Low risk: 6,11,uc 5 Yes
Kotloff et al
(1998)
USA 1992–93 C/s college 414 Mixed PCR MY09/11 Any 35 Yes Race, condom use, parity,
smoking, STDs, age at first
intercourse
Giuliano et al
(1999)
USA 1992–95 C/s clinic 971 Mixed HC High risk: 16,18+ 13 Yes Place of birth, marital status
Deacon et al
(2000)
UK 1987–93 C/s controls
b 384 Mixed PCR MY09/11 Any 47 No —
Richardson
(2000)
Canada 1992–93 C/s college 375 Mixed PCR MY09/11 Any 23 No —
High risk: 16, 18+ 12
Low risk: 6,11+,uc 13
Rousseau et al
(2000)
Brazil 1993+ Cumulative c/c 765 Mixed PCR MY09/11 High risk: 16, 18+ N/a No —
Low risk: 6, 11+ ,uc N/a
Sellors et al
(2000)
Canada 1998–99 C/s clinic 954 Mixed HC ll High risk: 16, 18+ 13 Yes Marital status, smoking
Giuliano et al
(2001, 2002)
USA/Mexico 1997–98 C/s clinic 2031 Mixed PCR MY09/11 Any 14 No —
High risk: 16, 18+ 12
Low risk: 6,11+ 3
Lazcano-Ponce
et al (2001)
Mexico 1996–99 C/s population 1340 Normal PCR L1 Any 13 Yes Marital status, parity, age at first
intercourse, socioeconomic
status
High risk: 16, 18+ 10
Low risk: 6,11+ 3
Peyton et al
(2001)
USA 1996–2000 C/s clinic 3671 Mixed PCR MY09/11 Any 39 Yes Race, education, income,
marital status, parity,
diaphragm use, STDs
High risk: 16, 18+ 27
Low risk: 6,11+ 15
Berrington et al
(2002)
UK 1984–91 C/s controls
b 393 Mixed Serology for E7
proteins
High risk: 16,18 11 Yes Smoking
Molano et al
(2002)
Colombia 1993–95 C/s population/
clinic
1845 Normal PCR GP5+/6+ Any 15 Yes Education, parity, condom use,
smoking, age at first intercourse High risk: 16, 18+ 11
Low risk: 6, 11+ 3
Moreno et al
(2002)
Multicentre 1985–97 C/s controls
b 1916 Normal PCR MY09/11,GP5+/6+ Any 13 No Centre
High risk: 16, 18+ 8
Low risk: 6, 11+ 5
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yceptives compared with never users. Studies are listed in order of
date of publication, earliest first. Black squares indicate relative
risks, the area of each square being proportional to the amount of
statistical information contributed, with horizontal lines indicating
95% confidence intervals. The method of empirically weighted
least squares (Cox and Snell, 1989) was used to test for
heterogeneity between relative risks.
RESULTS
Overall, 19 eligible studies were identified, with data on HPV status
and oral contraceptive use for a total of 20509 women (Kjaer et al,
1990, 1997; Ley et al, 1991; Karlsson et al, 1995; Burk et al, 1996;
Kotloff et al, 1998; Giuliano et al, 1999, 2001, 2002; Deacon et al,
2000; Richardson et al, 2000; Rousseau et al, 2000; Sellors et al,
2000; Lazcano-Ponce et al, 2001; Peyton et al, 2001; Berrington
et al, 2002; Molano et al, 2002; Moreno et al, 2002; Anh et al, 2003;
Shin et al, 2003). Details of the studies are given in Table 1. The
study by Moreno et al (2002) provided a pooled analysis of data on
control subjects from eight case–control studies of cervical cancer.
In two other studies, the subjects were also controls from case–
control studies of cervical cancer (Deacon et al, 2000; Berrington
et al, 2002). All studies measured prevalent HPV positivity, that is,
the numbers of women testing positive at one point in time, with
no distinction between recent and persistent infection; in the study
by Rousseau et al (2000), women becoming HPV positive within
the 12 months of study follow-up were also classed as HPV
positive. In four studies (Kjaer et al, 1997; Lazcano-Ponce et al,
2001; Molano et al, 2002; Moreno et al, 2002), all subjects had
normal cervical cytology; in the other studies, the proportion of
women with normal cytology ranged from 89 to 99%. In all but one
study, HPV DNA was detected in cervical specimens by
polymerase chain reaction (PCR)-based (15 studies) or hybridisa-
tion methods; in the study by Berrington et al (2002) and in part of
the study by Shin et al (2003), high-risk (genital) HPV types were
detected by serology.
The following analyses are based on the data presented in
published reports for the duration of use of oral contraceptives and
for ever, current and past use. In many studies, the information
provided was insufficient to allow inclusion of the study in all
analyses.
Figure 1 shows the relation between HPV positivity and ever use
of oral contraceptives in the seven studies that presented these
results. Results are shown for any HPV type, and separately for
high-risk and low-risk HPV types. There was considerable
variation between studies in the relative risks for HPV positivity
in ever users vs never users of oral contraceptives, and no
evidence for a strong positive or negative effect overall. Summary
relative risks for ever vs never use have not been calculated
as we do not feel that they would adequately reflect the variability
in results between studies. The results of a statistical test for
heterogeneity are included in this and subsequent figures
for information; it should be borne in mind that such tests
generally have a low sensitivity (Greenland, 1987) and should not
be used as the sole criterion of important heterogeneity between
studies.
Information on duration of use was available from eight
studies, of which only four included long duration. There was
no clear evidence for an effect of duration of oral contraceptive
use on the risk of HPV positivity (Figure 2). There was no
consistency between studies in apparent trend of HPV positivity
with duration of use, with individual studies showing increased,
decreased or unchanged risk of HPV positivity with increasing
duration of oral contraceptive use. The lack of information on long
duration use and the variability between study results mean that,
again, calculation of summary relative risks would not be
appropriate.
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yRelative risks for HPV positivity in relation to current and past
use of oral contraceptives are shown in Figure 3. Again there was
considerable variability between study results and no clear
evidence for a strong positive or negative association between
oral contraceptive use and HPV positivity.
Lack of information severely limited attempts to investigate
possible sources of heterogeneity within this analysis. Figures 4–6
show the results for ever use, duration of use and current use in the
15 studies that used PCR methods to detect HPV (all of the studies
with data on past use had used PCR). There were no obvious
A Any HPV type
B High-risk HPV types
C Low-risk HPV types
Study
Kjaer et al (1990)
Richardson et al (2000)
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
Shin et al (2003)
FISH
PCR
PCR
PCR
PCR
PCR
PCR
HPV measure Ever users Never users
HPV+ / HPV−
122/655
Not available
Not available
Not available Not available
Not available
Not available
31/268
1332/2129
92/610
139/706
4/37
37/300
137/904
182/220
163/1051
132/825
86/736
1.4 (0.9 − 2.2)
0.8 (0.4 − 1.4)
1.0 (0.6 − 1.6)
0.8 (0.7 − 1.1)
1.0 (0.8 − 1.4)
1.4 (1.1 − 1.9)
0.9 (0.3 − 2.5)
1.3 (0.8 − 2.0)
1.1 (0.5 − 2.5)
1.1 (0.7 − 1.8)
0.9 (0.7 − 1.2)
1.0 (0.7 − 1.5)
1.4 (1.0 − 1.9)
1.0 (0.5 − 2.2)
1.5 (0.8 − 2.6)
RR (95% CI) RR & 95% CI
Test for heterogeneity among all studies: χ2 = 12.2; P = 0.06
6
Test for heterogeneity among all studies: χ2 = 5.1; P > 0.1
6
Test for heterogeneity among all studies: χ2 = 8.1; P > 0.1
5
Kjaer et al (1990)
Richardson et al (2000)
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
Shin et al (2003)
FISH
PCR
PCR
PCR
PCR
PCR
Kjaer et al (1990)
Richardson et al (2000)
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
FISH
PCR
PCR
PCR
PCR
PCR
Serology
104/681
2/−
903/−
55/610
106/−
8/33
32/306
27/−
130/−
107/1051
99/−
162/660
67/765
27/−
491/−
30/− 29/−
76/−
110/−
37/610 56/1051
0.6 (0.3 − 1.3)
0.6 (0.1 − 2.9)
0.8 (0.6 − 1.1)
1.0 (0.6 − 1.6)
1.6 (0.9 − 2.9)
0.5 1 2 4 8
21/330
Figure 1 Relative risk (RR) and 95% confidence interval (CI) for (A) any type, (B) high-risk and (C) low-risk HPV positivity in ever users vs never users of
oral contraceptives.
A
B
C
Short duration (~<5 years of use)
Medium duration (~5 − 9 years of use)
Long duration (~10 or more years of use)
Study HPV measure HPV types
HPV+ / HPV −
Users Never users RR (95% CI) RR & 95% CI
Ley et al (1991)
Karlsson et al (1995)
Kjaer et al (1997)
Giuliano et al (1999)
Deacon et al (2000)
Rousseau et al (2000)
Berrington et al (2002)
Moreno et al (2002)
PCR
PCR
PCR
HC
PCR
PCR
Serology
PCR
Any
Any
Any
High risk
Any
High risk
High risk
Any
Ley et al (1991)
Karlsson et al (1995)
Kjaer et al (1997)
Giuliano et al (1999)
Deacon et al (2000)
Rousseau et al (2000)
Berrington et al (2002)
Moreno et al (2002)
Karlsson et al (1995)
Deacon et al (2000)
Berrington et al (2002)
Moreno et al (2002)
PCR
PCR
PCR
HC
PCR
PCR
Serology
PCR
PCR
PCR
Serology
PCR
Any
Any
Any
High risk
Any
Any
Any
High risk
Any
High risk
High risk
Any
121/113
58/207
74/391
66/414
38/51
56/261
18/141
64/309
38/104
18/86
17/135
46/206
35/38
7/64
8/41
163/1051
46/33
2.1 (1.3 − 3.5)
1.4 (0.7 − 2.5)
1.6 (0.9 − 2.8)
0.7 (0.4 − 1.1)
0.7 (0.3 − 1.3)
2.5 (1.0 − 5.8)
0.6 (0.2 − 1.6)
1.4 (0.9 − 1.9)
14/47
56/283
13/187
56/55
29/149
15/102
13/148
38/104
18/86
17/135
46/206
35/38
7/64
8/41
163/1051
2.5 (1.2 − 5.1)
1.4 (0.6 − 3.1)
2.0 (1.1 − 3.6)
0.4 (0.2 − 0.8)
0.9 (0.5 − 1.8)
3.4 (1.3 − 8.7)
0.7 (0.3 − 2.0)
0.6 (0.3 − 1.1)
2.0 (0.9 − 4.4)
0.9 (0.4 − 1.7)
0.2 (0.1 − 1.0)
0.7 (0.4 − 1.3)
16/38
52/59
4/64
15/141
18/86
35/38
8/41
163/1051
0.5 1248
Test for heterogeneity among all studies: χ2 = 19.5; P < 0.01
7
Test for heterogeneity among all studies: χ2 = 27.2; P < 0.001
7
Test for heterogeneity among all studies: χ2 = 8.3; P < 0.05
3
Figure 2 Relative risk (RR) and 95% confidence interval (CI) for HPV positivity for (A) short-, (B) medium- and (C) long-duration users vs never users of
oral contraceptives.
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the analysis of all 19 studies, although restriction to PCR-based
studies was associated with some reduction in statistical hetero-
geneity between studies. There were too few studies using non-
PCR measures of HPV positivity to allow a direct comparison of
PCR and non-PCR studies. The results from 10 of the 19 studies
had been adjusted for the lifetime number of sexual partners.
Restriction to these studies did not materially alter the findings
of this review, and there remained considerable variability
between studies. The number of studies available for each analysis
was, however, very limited (four studies with information on ever
use of oral contraceptives; four with information on short and
medium duration of use but only one with information on long
duration use; five with information on current and two with
information on past use). Lack of information meant that it was
not possible to attempt to assess the importance of the type of
population (normal or mixed cytology) or of adjustment for
factors such as socioeconomic status, smoking and reproductive
factors.
DISCUSSION
We found no evidence from available data for a strong positive or
negative association between the use of oral contraceptives and the
simultaneous or later detection of HPV on the cervix. In particular,
there was no clear evidence for an effect of duration of oral
contraceptive use on HPV positivity.
The present results must, however, be interpreted with caution.
Limited information was available for many of the analyses, and
there was considerable heterogeneity in study design and in
results. There are also a number of potentially important sources
of bias and confounding within the available data.
Study HPV measure HPV types Users Never users
HPV+ / HPV−
RR (95% CI) RR & 95% CI
Karlsson et al (1995)
Burk et al (1996)
Kotloff et al (1998)
Giuliano et al (1999)
Giuliano et al (2001, 2002)
Deacon et al (2000)
Deacon et al (2000)
Richardson et al (2000)
Sellors et al (2000)
Giuliano et al (2001, 2002)
Moreno et al (2002)
Moreno et al (2002)
Molano et al (2002)
Molano et al (2002)
Anh et al (2003)
Anh et al (2003)
PCR
PCR/S Blot
PCR
HC
PCR
PCR
HC
PCR
PCR
PCR
PCR
PCR
PCR
PCR
PCR
PCR
Any
Any
Any
High risk
Any
Any
High risk
Any
Any
Any
Any
Any
Any
Any
Any
Any
47/137
49/92
68/136
49/349
50/49
63/308
Not available Not available
Not available
Not available
79/380
24/206
28/105
9/22
96/116
82/741
132/825
163/1051
85/536
58/525
35/38
46/206
18/86 1.3 (0.9 − 2.0)
1.5 (1.0 − 2.3)
1.5 (0.9 − 2.5)
0.8 (0.5 − 1.1)
0.9 (0.5 − 1.9)
0.7 (0.4 − 1.1)
1.7 (1.1 − 2.6)
1.2 (0.9 − 1.7)
0.9 (0.6 − 1.6)
1.5 (0.9 − 2.4)
2.9 (1.1 − 7.2)
133/818
61/368
111/610
10/58
35/38
85/536
163/1051
132/825
82/741
0.8 (0.4 − 1.4)
1.2 (0.9 − 1.6)
1.0 (0.7 − 1.5)
1.4 (1.0 − 1.9)
1.5 (0.7 − 3.2)
0.5
Test for heterogeneity among all studies: χ2  = 20.2; P < 0.05
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Test for heterogeneity among all studies: χ2 = 3.8; P > 0.1
4
Current users
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Figure 3 Relative risk (RR) and 95% confidence interval (CI) for HPV positivity in (A) current and (B) past users vs never users of oral contraceptives.
Study Ever users Never users
HPV+ / HPV−
RR (95% CI) RR & 95% CI
Richardson et al (2000)
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
Richardson et al (2000)
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
Richardson et al (2000)
Low-risk HPV types
High-risk HPV types
Lazcano-Ponce et al (2001)
Peyton et al (2001)
Moreno et al (2002)
Molano et al (2002)
Shin et al (2003)
Not available
Not available
Not available
Not available
Not available
Not available
31/268
1332/2129
92/610
139/706
4/37
2/−
137/904
182/220
163/1051
132/825
86/736
0.8 (0.4 − 1.4)
1.0 (0.6 − 1.6)
0.8 (0.7 − 1.1)
1.0 (0.8 − 1.4)
1.4 (1.1 − 1.9)
0.9 (0.3 − 2.5)
1.1 (0.5 − 2.5)
1.1 (0.7 − 1.8)
0.9 (0.7 − 1.2)
1.0 (0.7 − 1.5)
1.4 (1.0 − 1.9)
0.6 (0.3 − 1.3)
903/−
55/610
106/−
27/−
99/−
107/1051
130/−
27/−
491/−
37/610
30/− 29/−
56/1051
76/−
110/− 0.6 (0.1 − 2.9)
0.8 (0.6 − 1.1)
1.0 (0.6 − 1.6)
1.6 (0.9 − 2.9)
Test for heterogeneity among all studies: χ2 = 10.1; P = 0.07
5
Test for heterogeneity among all studies: χ2 = 4.4; P > 0.1
4
Test for heterogeneity among all studies: χ2 = 5.6; P > 0.1
4
C
B
A Any HPV type
0.5 1 2 4 8
Figure 4 Relative risk (RR) and 95% confidence interval (CI) for (A) for any type, (B) high-risk and (C) low-risk HPV positivity in ever users vs never users
of oral contraceptives, restricted to PCR studies.
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to age, with younger women having a higher prevalence, especi-
ally of high-risk HPV types (Melkert et al, 1993; Jacobs et al, 2000;
Chan et al, 2002); and so is oral contraceptive use. Although this
review has included only results adjusted for age (or, in two
studies, restricted to women within a narrow age range), the degree
of adjustment in most studies was probably insufficient to account
fully for potential confounding. Most studies used 5–10 year
age bands for adjustment and there is evidence that HPV
prevalence may vary widely within such bands (Ley et al, 1991;
Melkert et al, 1993). Residual confounding by age is particularly
important in the analyses of the effects of duration of use of oral
contraceptives, as short-duration users will tend to be younger
than long-duration users.
Sexual activity is an important potential confounding factor in
the studies considered here. The number of male sexual partners,
in particular, is a major risk factor for cervical HPV infection
(IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans, 1995) and oral contraceptive use is related to sexual
behaviour (Swan and Brown, 1981; Svare et al, 1997), although it
seems likely that the nature of this relation varies substantially
with age, time and place (Oddens and Lehert, 1997; Spinelli et al,
2000). We found no obvious difference in results between studies
with adjustment for the lifetime number of sexual partners and
those without in this review, but the information available was
insufficient to address this question fully.
The relation between duration of oral contraceptive use and
HPV positivity may be critical in understanding the epidemio-
logical and aetiological relations between oral contraceptives and
HPV infection. Related to this is the question of the possible effects
of oral contraceptive use on the persistence and detectability of
HPV infection. The studies reviewed here provide very limited
A Short duration (~<5 years of use)
Study HPV types
HPV+ / HPV −
Users Never users RR (95% CI) RR & 95% CI
Ley et al (1991) Any
Any
Any
Any
High risk
Any
Any
Any
Any
Any
Any
Any
Any
High risk
Any
Karlsson et al (1995)
Kjaer et al (1997)
Deacon et al (2000)
Rousseau et al (2000)
Moreno et al (2002)
Ley et al (1991)
Karlsson et al (1995)
Kjaer et al (1997)
Deacon et al (2000)
Rousseau et al (2000)
Moreno et al (2002)
Karlsson et al (1995)
Deacon et al (2000)
Moreno et al (2002)
121/113
58/207
74/391
38/51
56/261
64/309
38/104
18/86
17/135
35/38
7/64
163/1051
2.1 (1.3 − 3.5)
1.4 (0.7 − 2.5)
1.6 (0.9 − 2.8)
0.7 (0.3 − 1.3)
2.5 (1.0 − 5.8)
1.4 (0.9 − 1.9)
46/33
14/47
56/283
56/55
29/149
13/148
38/104
18/86
17/135
35/38
7/64
163/1051
18/86
2.5 (1.2 − 5.1)
1.4 (0.6 − 3.1)
2.0 (1.1 − 3.6)
0.9 (0.5 − 1.8)
3.4 (1.3 − 8.7)
0.6 (0.3 − 1.1)
2.0 (0.9 − 4.4)
0.9 (0.4 − 1.7)
0.7 (0.4 − 1.3)
35/38
163/1051
16/38
52/59
15/141
Test for heterogeneity among all studies: χ2 = 8.8; P > 0.1
5
Test for heterogeneity among all studies: χ2 = 15.7; P < 0.01
5
Test for heterogeneity among all studies: χ2 = 4.4; P > 0.1
2
B Medium duration (~5 − 9 years of use)
C Long duration (~10 or more years of use)
0.5 1248
Figure 5 Relative risk (RR) and 95% confidence interval (CI) for HPV positivity for (A) short-, (B) medium- and (C) long-duration users vs never users of
oral contraceptives, restricted to PCR studies.
Study HPV types Users Never users
HPV+ / HPV−
RR (95% CI) RR & 95% CI
Karlsson et al (1995)
Burk et al (1996)
Kotloff et al (1998)
Deacon et al (2000)
Richardson et al (2000)
Giuliano et al (2001, 2002)
Moreno et al (2002)
Molano et al (2002)
Anh et al (2003)
Any
Any
Any
Any
Any
Any
Any
Any
Any
47/137
49/92
68/136
50/49
Not available Not available
Not available
Not available
79/380
24/206
28/105
9/22 82/741
132/825
163/1051
85/536
35/38
18/86 1.3 (0.9 − 2.0)
1.5 (1.0 − 2.3)
1.5 (0.9 − 2.5)
0.9 (0.5 − 1.9)
0.7 (0.4 − 1.1)
1.2 (0.9 − 1.7)
0.9 (0.6 − 1.6)
1.5 (0.9 − 2.4)
2.9 (1.1 − 7.2)
Test for heterogeneity among all studies: χ2  = 12.5; P > 0.1 8
Current users
0.5 12 48
Figure 6 Relative risk (RR) and 95% confidence interval (CI) for HPV positivity in current users vs never users of oral contraceptives, restricted to PCR
studies.
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one exception) deal only with prevalent HPV positivity measured
at varying times in relation to oral contraceptive use. Insufficient
information was available to allow investigation of possible
differences between the risks for high-risk and low-risk HPV
positivity in the analyses of duration of use or of current or past
use of oral contraceptives, although patterns of infection may
differ between high-risk and low-risk HPV types (Elfgren et al,
2000; Jacobs et al, 2000).
For completeness, we have included in this review studies using
different methods of detection of HPV. Differences in sensitivity
and specificity between PCR-based and non-PCR-based tests could
introduce bias as misclassification of subjects as HPV positive or
negative will tend to attenuate a true association between a risk
factor and HPV status. In this review, restriction to PCR-based
studies did not materially alter the results. Differential misclassi-
fication, in which the sensitivity or specificity of an HPV test is
itself related to the risk factor being studied, in this case to oral
contraceptive use, remains a possible source of bias within studies
using any method of HPV detection.
In evaluating the relation between oral contraceptive use and
HPV infection, it may be appropriate to include, where possible,
studies using different methods of HPV detection as these may
reflect different aspects of HPV infection. Serological studies are
thought to measure cumulative lifetime exposure to HPV
(although it is not clear to what extent persistence of infection is
reflected in antibody response), whereas measures of cervical HPV
DNA are likely to reflect current and persistent past infection (Shin
et al, 2003). Non-PCR methods of detecting HPV DNA may
preferentially detect infections of high viral load and these may be
of particular clinical significance (Ylitalo et al, 2000; Lorincz et al,
2002).
The relation between oral contraceptive use and the use of
barrier methods of contraception is a potential source of
confounding, and it has not been possible to address this here.
In some populations, nonusers of oral contraceptives are likely to
use barrier methods, and as many as a third of young oral
contraceptive users in some recent studies report also using
condoms (Peipert et al, 1997; Svare et al, 1997). Since barrier
contraceptives may reduce the risk of HPV transmission (Manhart
and Koutsky, 2002), such associations may be important.
Most eligible studies included some women with cytological
abnormalities; while the number of women with severe grades of
cytological abnormality (cervical intraepithelial neoplasia (CIN) 3,
high-grade squamous cell intraepithelial lesions (HSIL) or above)
was very small (typically about 1%), the strong association
between cervical cancer and HPV means that they accounted for
up to 10% of the HPV-positive women in these studies. This seems
unlikely to prove a significant source of bias in the measured
relation between oral contraceptive use and HPV. Low-grade
cytological abnormalities (CIN1/2, LSIL), which may be present in
up to 10% of women in these unselected populations, and which
may account for a further 10% of HPV positives in these
populations, may simply indicate HPV infection and should
probably not be considered a possible source of bias.
There are a number of hypotheses but little direct evidence
about the ways in which oral contraceptives might influence
cervical HPV infection. The use of oral contraceptives is associated
with an increased incidence of cervical ectropion, which means
that the site where HPV infection preferentially induces neoplastic
lesions, the squamo-columnar junction, is more exposed to
potential carcinogens. Oestrogen and progestogens may also affect
cervical cells directly, increasing cell proliferation and stimulating
transcription of HPVs (de Villiers, 2003). Oral contraceptives
might thus affect not only viral infection and malignant
transformation of cervical cells but also the sensitivity or
specificity of tests for detecting HPV infection.
In conclusion, this review provides preliminary evidence
suggesting that there is no strong positive or negative relation
between oral contraceptive use and prevalent infection of the
cervix with HPV. Given that HPV infection appears to be a
necessary cause of most cases of cervical cancer, this finding, if
true, is of considerable importance as it suggests that HPV status is
not likely to confound examination of the relation between long
duration use of oral contraceptives and the risk of cervical cancer.
However, there are serious problems in interpreting these results
and further evidence is needed to address the methodological and
other issues raised.
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